PVLA PALVELLA THERAPEUTICS, INC.

8-K Current Report

Filed: February 24, 2026

Health Care

Pharmaceutical Preparations

PALVELLA THERAPEUTICS, INC. (PVLA) 8-K current report filed with SEC EDGAR on February 24, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• Phase 3 SELVA study of QTORIN™ 3.9% rapamycin anhydrous gel in microcystic lymphatic malformations reported positive topline results
• Positive Phase 3 readout is a pivotal milestone — typically triggers NDA/BLA filing consideration and potential partnering or approval catalysts

+1 more insights

Other PALVELLA THERAPEUTICS, INC. 8-K Filings

8-K Feb 26, 2026

8-K Feb 24, 2026

Get deeper insights on PALVELLA THERAPEUTICS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.